GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 8 shares of the stock in a transaction dated Tuesday, July 9th. The stock was purchased at an average cost of GBX 1,636 ($21.38) per share, with a total value of £130.88 ($171.02).

Emma Walmsley also recently made the following trade(s):

  • On Tuesday, June 11th, Emma Walmsley bought 7 shares of GlaxoSmithKline stock. The stock was purchased at an average cost of GBX 1,585 ($20.71) per share, with a total value of £110.95 ($144.98).
  • On Friday, May 10th, Emma Walmsley bought 9 shares of GlaxoSmithKline stock. The stock was purchased at an average cost of GBX 1,512 ($19.76) per share, with a total value of £136.08 ($177.81).

Shares of GlaxoSmithKline stock opened at GBX 1,632.40 ($21.33) on Friday. The company has a current ratio of 0.72, a quick ratio of 0.45 and a debt-to-equity ratio of 942.07. GlaxoSmithKline plc has a 12 month low of GBX 1,408.80 ($18.41) and a 12 month high of GBX 1,651 ($21.57). The business’s fifty day moving average is GBX 1,583.69. The firm has a market capitalization of $81.44 billion and a PE ratio of 20.79.

The business also recently disclosed a dividend, which was paid on Thursday, July 11th. Investors of record on Thursday, May 16th were paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date was Thursday, May 16th. This represents a dividend yield of 1.22%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 0.97%.

Several research firms have recently commented on GSK. Bryan, Garnier & Co lowered their target price on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a “neutral” rating for the company in a research note on Thursday, May 2nd. Kepler Capital Markets lifted their price objective on GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the stock a “hold” rating in a research note on Tuesday, June 11th. HSBC set a €16.50 ($19.19) price objective on UniCredit and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Liberum Capital reaffirmed a “hold” rating on shares of Daily Mail and General Trust P L C in a research note on Tuesday, July 2nd. Finally, Barclays lifted their price objective on Intuit from $225.00 to $237.00 and gave the stock an “equal weight” rating in a research note on Friday, May 24th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of GBX 1,535.88 ($20.07).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Story: Return on Investment (ROI)

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.